2013 Fiscal Year Final Research Report
Development of the new cancer immunotherapy using fusion cell-vaccine of iPSDC and cancer stem cell
| Project/Area Number |
23591874
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAUE Hiroki 和歌山県立医科大学, 医学部, 教授 (20191190)
IWAHASHI Makoto 和歌山県立医科大学, 医学部, 研究員 (70244738)
NAKAMORI Mikito 和歌山県立医科大学, 医学部, 講師 (10322372)
OJIMA Toshiyasu 和歌山県立医科大学, 医学部, 講師 (60448785)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | ｉＰＳ細胞 / 樹状細胞 / 癌免疫療法 |
|---|
| Research Abstract |
It is generally accepted that the difficulty in obtaining a sufficient number of functional dendritic cells (DCs) is a serious problem in DC-based immunotherapy. We used the induced pluripotent stem (iPS) cell-derived DCs (iPSDCs). In this study, we examined the capacity of iPSDCs compared with that of bone marrow-derived DCs (BMDCs). We adenovirally transduced the hgp100 gene into DCs and immunized mice once with the genetically modified DCs. The cytotoxic activity of CD8 (+) cytotoxic T lymphocytes (CTLs) and the therapeutic efficacy of the vaccination were assayed. Our results showed that hgp100-specific CTLs exhibited as high a level of cytotoxicity as BMDCs. Moreover, vaccination with the genetically modified iPSDCs achieved as high a level of therapeutic efficacy as vaccination with BMDCs. This study clarified experimentally that iPSDCs have an equal capacity to BMDCs. This vaccination strategy may therefore be useful for future clinical application as a cancer vaccine.
|
Research Products
(8 results)
